{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:19:37Z","timestamp":1792513177684,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis independently influences survival outcomes in patients with ovarian cancer and investigated the clinicopathologic characteristics of endometriosis-associated ovarian tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients treated for primary malignant or borderline ovarian tumors between January 2014 and July 2025 at a tertiary ESGO-accredited German academic center. Concurrent endometriosis was defined by histologic confirmation at primary surgery and classified as endometriosis-correlated ovarian tumors when histopathologic a transitional lesion from endometriosis to tumor was identified, or as endometriosis-incidental ovarian tumors when endometriosis was identified without transitional lesions. An age-matched reference cohort without endometriosis (1:5) was used for comparison. Survival analyses were restricted to patients with epithelial ovarian cancer and performed using Kaplan\u2013Meier estimates and multivariable Cox regression, adjusting for age, histologic subtype, FIGO stage, endometriosis status, and surgical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2,164 eligible patients, 176 (8.1%) had histologically confirmed endometriosis, including 22 (1.0%) endometriosis-correlated ovarian tumors and 154 (7.1%) endometriosis-incidental ovarian tumors. Patients with endometriosis were significantly younger and more frequently diagnosed with early-stage disease and endometrioid or clear cell histology compared with patients without endometriosis. Endometriosis-correlated ovarian tumors showed a high prevalence of ovarian endometriosis, the absence of p53 aberrations, and no BRCA1\/2 mutations. Median overall survival was not reached for patients with endometriosis-correlated ovarian tumors or endometriosis-incidental ovarian tumors. After multivariable adjustment, neither endometriosis-correlated ovarian tumors nor endometriosis-incidental ovarian tumors was independently associated with overall or disease-free survival. Advanced FIGO stage, older age, and incomplete cytoreduction were independently associated with worse survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Endometriosis-associated ovarian tumors show favorable clinicopathologic features but concurrent endometriosis is not an independent prognostic factor for survival in patients with ovarian cancer. Prognosis appears to be driven primarily by tumor biology, stage, and surgical outcome rather than the presence of endometriosis itself.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15980-w","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:43:51Z","timestamp":1776311031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-0046","authenticated-orcid":false,"given":"Maximilian Heinz","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kordowitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Roser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Trelinska-Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Schoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Chinczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Mechsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"13","key":"15980_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMra1810764","volume":"382","author":"KT Zondervan","year":"2020","unstructured":"Zondervan KT, Becker CM, Missmer SA. Endometriosis N Engl J Med. 2020;382(13):1244\u201356.","journal-title":"Endometriosis N Engl J Med"},{"issue":"10276","key":"15980_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(21)00389-5","volume":"397","author":"HS Taylor","year":"2021","unstructured":"Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet. 2021;397(10276):839\u201352.","journal-title":"Lancet"},{"key":"15980_CR3","doi-asserted-by":"crossref","unstructured":"Pejovic T et al. Genetic Links between Endometriosis and Endometriosis-Associated Ovarian Cancer-A Narrative Review (Endometriosis-Associated Cancer). Life (Basel), 2024. 14(6).","DOI":"10.3390\/life14060704"},{"issue":"7","key":"15980_CR4","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/bjc.2014.29","volume":"110","author":"HS Kim","year":"2014","unstructured":"Kim HS, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer. 2014;110(7):1878\u201390.","journal-title":"Br J Cancer"},{"issue":"4","key":"15980_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","volume":"13","author":"CL Pearce","year":"2012","unstructured":"Pearce CL, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385\u201394.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15980_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jama.2024.9210","volume":"332","author":"ME Barnard","year":"2024","unstructured":"Barnard ME, et al. Endometriosis Typology and Ovarian Cancer Risk. JAMA. 2024;332(6):482\u20139.","journal-title":"JAMA"},{"key":"15980_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1757-2215-3-2","volume":"3","author":"A Aris","year":"2010","unstructured":"Aris A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010;3:2.","journal-title":"J Ovarian Res"},{"issue":"2","key":"15980_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/humupd\/dmaa045","volume":"27","author":"M Kvaskoff","year":"2021","unstructured":"Kvaskoff M, et al. Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(2):393\u2013420.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"15980_CR9","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1016\/j.ajog.2020.01.041","volume":"223","author":"M Hermens","year":"2020","unstructured":"Hermens M, et al. Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study. Am J Obstet Gynecol. 2020;223(1):e1071\u201310711.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"15980_CR10","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s43032-024-01489-9","volume":"31","author":"F Chiaffarino","year":"2024","unstructured":"Chiaffarino F, et al. Histologic Subtypes in Endometriosis-Associated Ovarian Cancer and Ovarian Cancer Arising in Endometriosis: A Systematic Review and Meta-Analysis. Reprod Sci. 2024;31(6):1642\u201350.","journal-title":"Reprod Sci"},{"issue":"4","key":"15980_CR11","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.ijgc.2025.101634","volume":"35","author":"F Mezzapesa","year":"2025","unstructured":"Mezzapesa F, et al. Two possible entities of endometriosis-associated ovarian cancer: correlated or incidental? Int J Gynecol Cancer. 2025;35(4):101634.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"15980_CR12","doi-asserted-by":"publisher","first-page":"e1002893","DOI":"10.1371\/journal.pmed.1002893","volume":"16","author":"J Yarmolinsky","year":"2019","unstructured":"Yarmolinsky J, et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Med. 2019;16(8):e1002893.","journal-title":"PLoS Med"},{"issue":"1","key":"15980_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1055\/s-0036-1597120","volume":"35","author":"MA Wilbur","year":"2017","unstructured":"Wilbur MA, et al. Cancer Implications for Patients with Endometriosis. Semin Reprod Med. 2017;35(1):110\u20136.","journal-title":"Semin Reprod Med"},{"key":"15980_CR14","doi-asserted-by":"publisher","first-page":"1329133","DOI":"10.3389\/fonc.2024.1329133","volume":"14","author":"B Chen","year":"2024","unstructured":"Chen B, et al. New insights about endometriosis-associated ovarian cancer: pathogenesis, risk factors, prediction and diagnosis and treatment. Front Oncol. 2024;14:1329133.","journal-title":"Front Oncol"},{"issue":"1","key":"15980_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13048-021-00865-2","volume":"14","author":"KA So","year":"2021","unstructured":"So KA, et al. Association between atypical endometriosis and ovarian malignancies in the real world. J Ovarian Res. 2021;14(1):110.","journal-title":"J Ovarian Res"},{"issue":"10","key":"15980_CR16","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.7150\/ijms.97024","volume":"21","author":"H Yang","year":"2024","unstructured":"Yang H, et al. Identification and Validation of Prognostic Markers for Endometriosis-Associated Ovarian Cancer. Int J Med Sci. 2024;21(10):1903\u201314.","journal-title":"Int J Med Sci"},{"key":"15980_CR17","doi-asserted-by":"publisher","first-page":"732322","DOI":"10.3389\/fonc.2022.732322","volume":"12","author":"P Chen","year":"2022","unstructured":"Chen P, Zhang CY. Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis. Front Oncol. 2022;12:732322.","journal-title":"Front Oncol"},{"key":"15980_CR18","doi-asserted-by":"crossref","unstructured":"Hablase R et al. The Road to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review. Cancers (Basel), 2024. 16(11).","DOI":"10.3390\/cancers16112160"},{"issue":"19","key":"15980_CR19","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1614814","volume":"376","author":"MS Anglesio","year":"2017","unstructured":"Anglesio MS, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med. 2017;376(19):1835\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"15980_CR20","first-page":"283","volume":"2","author":"RB Scott","year":"1953","unstructured":"Scott RB. Malignant changes in endometriosis. Obstet Gynecol. 1953;2(3):283\u20139.","journal-title":"Obstet Gynecol"},{"issue":"10","key":"15980_CR21","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/sj.bjc.6603457","volume":"95","author":"JK Chan","year":"2006","unstructured":"Chan JK, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314\u201320.","journal-title":"Br J Cancer"},{"issue":"1","key":"15980_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2019.12.047","volume":"157","author":"CJ Cabasag","year":"2020","unstructured":"Cabasag CJ, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. Gynecol Oncol. 2020;157(1):234\u201344.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"15980_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1525-1438.2007.00912.x","volume":"17","author":"D Pectasides","year":"2007","unstructured":"Pectasides D, et al. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer. 2007;17(5):1003\u201310.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"15980_CR24","first-page":"436","volume":"75","author":"P Kordowitzki","year":"2025","unstructured":"Kordowitzki P, et al. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin. 2025;75(5):436\u201360.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"15980_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cjp2.311","volume":"9","author":"M Kobel","year":"2023","unstructured":"Kobel M, et al. 53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2023;9(3):208\u201322.","journal-title":"J Pathol Clin Res"},{"key":"15980_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","volume":"80","author":"J Prat","year":"2018","unstructured":"Prat J, D\u2019Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11\u201327.","journal-title":"Hum Pathol"},{"issue":"1","key":"15980_CR27","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","volume":"11","author":"RL Hollis","year":"2020","unstructured":"Hollis RL, et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat Commun. 2020;11(1):4995.","journal-title":"Nat Commun"},{"issue":"1","key":"15980_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5545","volume":"253","author":"D Cheasley","year":"2021","unstructured":"Cheasley D, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol. 2021;253(1):41\u201354.","journal-title":"J Pathol"},{"issue":"7353","key":"15980_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","unstructured":"Cancer Genome Atlas Research. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"16","key":"15980_CR30","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"15980_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/path.2940","volume":"225","author":"S Yamamoto","year":"2011","unstructured":"Yamamoto S, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol. 2011;225(2):189\u201394.","journal-title":"J Pathol"},{"issue":"4","key":"15980_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/modpathol.2011.189","volume":"25","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto S, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25(4):615\u201324.","journal-title":"Mod Pathol"},{"issue":"11","key":"15980_CR33","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222\u201345.","journal-title":"J Clin Oncol"},{"key":"15980_CR34","doi-asserted-by":"publisher","first-page":"1381244","DOI":"10.3389\/fonc.2024.1381244","volume":"14","author":"L Tang","year":"2024","unstructured":"Tang L, Bian C. Research progress in endometriosis-associated ovarian cancer. Front Oncol. 2024;14:1381244.","journal-title":"Front Oncol"},{"key":"15980_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejogrb.2020.08.019","volume":"253","author":"S Maruyama","year":"2020","unstructured":"Maruyama S, et al. Relationship between adenomyosis and endometriosis; Different phenotypes of a single disease? Eur J Obstet Gynecol Reprod Biol. 2020;253:191\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"15980_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.fertnstert.2023.03.006","volume":"119","author":"SE Bulun","year":"2023","unstructured":"Bulun SE, et al. Endometriosis and adenomyosis: shared pathophysiology. Fertil Steril. 2023;119(5):746\u201350.","journal-title":"Fertil Steril"},{"issue":"3","key":"15980_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ygyno.2021.07.006","volume":"162","author":"M Hermens","year":"2021","unstructured":"Hermens M, et al. Increased incidence of ovarian cancer in both endometriosis and adenomyosis. Gynecol Oncol. 2021;162(3):735\u201340.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"15980_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ijgo.15756","volume":"167","author":"C Harder","year":"2024","unstructured":"Harder C, et al. Assessing the true prevalence of endometriosis: A narrative review of literature data. Int J Gynaecol Obstet. 2024;167(3):883\u2013900.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"15980_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajog.2021.06.067","volume":"225","author":"JP Christ","year":"2021","unstructured":"Christ JP, et al. Incidence, prevalence, and trends in endometriosis diagnosis: a United States population-based study from 2006 to 2015. Am J Obstet Gynecol. 2021;225(5):500\u2013500. e1-e9.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"15980_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/aogs.14364","volume":"101","author":"LRH Illum","year":"2022","unstructured":"Illum LRH, et al. Temporal and regional differences in the incidence of hospital-diagnosed endometriosis: a Danish population-based study. Acta Obstet Gynecol Scand. 2022;101(7):737\u201346.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"15980_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41416-025-03082-6","volume":"133","author":"B Narayanan","year":"2025","unstructured":"Narayanan B, et al. Growth kinetics of high-grade serous ovarian cancer: implications for early detection. Br J Cancer. 2025;133(4):533\u20138.","journal-title":"Br J Cancer"},{"issue":"6","key":"15980_CR42","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/1471-0528.13447","volume":"123","author":"A Lim","year":"2016","unstructured":"Lim A, et al. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG. 2016;123(6):1012\u201320.","journal-title":"BJOG"},{"issue":"6","key":"15980_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ijgc-2023-005139","volume":"34","author":"R Leone","year":"2024","unstructured":"Leone R, Maggiore U, et al. Endometriosis-associated ovarian cancer: a different clinical entity. Int J Gynecol Cancer. 2024;34(6):863\u201370.","journal-title":"Int J Gynecol Cancer"},{"key":"15980_CR44","doi-asserted-by":"crossref","unstructured":"Pariza G et al. A Narrative Review of Clinical and Molecular Criteria for the Selection of Poor Candidates for Optimal Cytoreduction in Epithelial Ovarian Cancer. Life (Basel), 2025. 15(8).","DOI":"10.3390\/life15081318"},{"issue":"6","key":"15980_CR45","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344.","journal-title":"Cancer"},{"key":"15980_CR46","doi-asserted-by":"crossref","unstructured":"Andreou M et al. Prognostic Factors Influencing Survival in Ovarian Cancer Patients: A 10-Year Retrospective Study. Cancers (Basel), 2023. 15(24).","DOI":"10.3390\/cancers15245710"},{"key":"15980_CR47","doi-asserted-by":"crossref","unstructured":"Mezzapesa F et al. Mesonephric-like adenocarcinoma of the ovary: features of a rare and aggressive entity associated with endometriosis. Int J Gynecol Cancer, 2025: p. 101990.","DOI":"10.1016\/j.ijgc.2025.101990"},{"issue":"1","key":"15980_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0090-8258(90)90126-6","volume":"36","author":"G Baiocchi","year":"1990","unstructured":"Baiocchi G, Kavanagh JJ, Wharton JT. Endometrioid stromal sarcomas arising from ovarian and extraovarian endometriosis: report of two cases and review of the literature. Gynecol Oncol. 1990;36(1):147\u201351.","journal-title":"Gynecol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15980-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:08:35Z","timestamp":1781647715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15980-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15980"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15980-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local institutional ethics committee of Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany (Vote EA2\/266\/22) and conducted in accordance with the Declaration of Helsinki. The institutional ethics committee of Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin (Vote EA2\/266\/22) waived the requirement for written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"495"}}